Tag: Alnylam Pharmaceuticals

January 21, 2019

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an...
November 25, 2018

What is In-licensing?

In-licensing may be pharma’s preferred mode of business development these days. Should that impact your investment strategy?
October 15, 2018

Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that in consultation with the U.S. Food and Drug Administration (FDA),...
September 14, 2018

Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran

Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today publication of data from exploratory cardiac assessments in the APOLLO...
August 21, 2018

Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

Alnylam Pharmaceuticals (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has achieved full patient accrual in its ENVISION Phase...
August 13, 2018

Alnylam Pharma Receives FDA Approval for Onpattro

On Friday, Alnylam Pharmaceuticals received US Food and Drug Administration approval for Onpattro (patisiran).
August 13, 2018

Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis

Arbutus Biopharma (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company’s lipid nanoparticle (LNP)...